Pembrolizumab‐induced interstitial lung disease following thoracic surgery in a patient with non‐small cell lung cancer

The safety of treatment with immune‐checkpoint inhibitors prior to thoracic surgery in patients with non‐small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62‐year‐old woman with NSCLC with programmed death ligand 1 expression on 85% of tumor cells. The patient was initi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Thorac Cancer
Prif Awduron: Fujita, Tetsuo, Hayama, Nami, Kuroki, Tsuguko, Shiraishi, Yuka, Amano, Hiroyuki, Nakamura, Makoto, Hirano, Satoshi, Aramaki, Nao, Ichinose, Shuji, Shimizu, Shinichiro, Tabeta, Hiroshi, Nakamura, Sukeyuki
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons Australia, Ltd 2019
Pynciau:
Case Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825914/
https://ncbi.nlm.nih.gov/pubmed/31512401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13194
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg